Skip to main content
  • Meeting abstract
  • Open access
  • Published:

PW02-042 - Induction of MDSC in Muckle-Wells syndrome

Introduction

Muckle-Wells syndrome (MWS) is caused by mutations in the NLRP3-gene encoding cryopyrin, leading to overproduction of IL-1β and other NLRP3 inflammasome products. Myeloid-derived suppressor cells (MDSCs) represent a novel innate immune cell subset, are generated in tumor, infective, and proinflammatory microenvironments and are capable of suppressing T cell responses. Consequently, MDSCs are considered a key intermediary in balancing innate and adaptive immune responses, particularly under chronic disease conditions.

Objectives

We hypothesized that NLRP3 inflammasome-dependent factors induce the generation of MDSCs in MWS.

Methods

We studied granulocytic MDSC numbers in 25 MWS patients under anti-IL-1 therapy with canakinumab and 20 healthy controls. After Ficoll density gradient sedimentation, granulocytic MDSCs were characterized as CD33highCD66bhighIL-4RainterHLA-DRlow neutrophilic cells in the PBMC fraction, according to previously established human MDSC analysis methods. The functionality of MACS-isolated MDSCs was assessed using polyclonal T cell proliferation and cytokine / chemokine secretion tests. Physician’s global assessment of disease activity, CRP, ESR, and T helper cell subsets were determined at the same time points and correlated with MDSC levels. Serum samples of 22 MWS patients and 5 healthy controls were examined by multiplex technique for possible MDSC inducing factors.

Results

MWS patients under anti-IL-1 therapy displayed significantly elevated MDSC numbers (mean 1.65 ± 0.33 %; range 0.16 – 5.17 %) compared to healthy controls (mean 0.45 ± 0.05 %; range 0.12 – 1.04%; p = 0.0025), although clinical MWS-disease activity was generally low at time of examination. MDSCs were functionally competent, as they suppressed polyclonal T cell proliferation, Th1, Th2, and Th17 responses. MDSCs correlated directly with Treg/Th17 and Treg/Th1 ratios indicating an influence on T helper cell subsets. Multiplex assays revealed the established MDSC-inducing growth factors GM-CSF and VEGF elevated in MWS sera even under anti-IL-1 therapy with canakinumab.

Conclusion

MWS patients under anti-IL-1 therapy display significantly elevated numbers of granulocytic MDSCs. Increased MDSCs in MWS might represent a novel autologous anti-inflammatory mechanism in autoinflammatory conditions and may serve as a future therapeutic target.

Author information

Authors and Affiliations

Authors

Additional information

Competing interests

N. Rieber Grant / Research Support from: I obtained research grant from Novartis GmbH in 2012, Paid Instructor at: I held a paid talk for Novartis GmbH in 2012, A. Brand: None declared, D. Neri: None declared, T. Hall: None declared, I. Schäfer: None declared, S. Hansmann: None declared, J. Kümmerle-Deschner Grant / Research Support from: Obtained research grants from Novartis GmbH, D. Hartl Grant / Research Support from: Obtained research grants from Novartis GmbH

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Rieber, N., Brand, A., Neri, D. et al. PW02-042 - Induction of MDSC in Muckle-Wells syndrome. Pediatr Rheumatol 11 (Suppl 1), A183 (2013). https://doi.org/10.1186/1546-0096-11-S1-A183

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1546-0096-11-S1-A183

Keywords